Investors rethink obesity bets

Several factors dampen investor appetite for the obesity trade.

TODAY’S STORY

Investors are losing their appetite for the obesity trade.

Shares in both companies have decreased significantly after last month's lackluster weight-loss trial of a new Novo Nordisk drug and slower-than-expected Q4 revenue from Eli Lilly.

Other external factors are making investors more nervous. Both have increased their U.S. advertising spend, but investors have not seen the corresponding sales bump. Nordisk’s Wegovy and Ozempic were also recently added to the Medicare negotiation list this month, likely causing prices to decline starting in 2027.

There’s also considerable debate around market size—will the obesity drug market be $100Bn by the end of the decade, or is it closer to $80Bn?

There's potential profit on both sides of the trade, but the easy gains are behind us. We're now heading into more turbulent and uncertain conditions.

OUR PICKS

Here are today’s recs to help you live a smarter life…

1. Lightweight and pocket-sized.

The SanDisk Extreme Pro Portable SSD provides a dependable storage solution featuring up to 2,000MB/s read/write speeds. $80 off for a limited time.*

2. Elevate your outdoor space.

This outdoor gas heater is excellent for home patios, provides cozy warmth when sitting outside, and comes with tip-over protection.*

3. Built for accuracy, designed for your every day.

The Oura Ring tracks your sleep, activity, stress, heart rate, and more.*

#SHORTS

Hotel booking sites caught overcharging travelers

@boringbusinesskieran

Hotel booking sites caught overcharging travelers 📌 #business #hotel #travel #pricing #personalfinance #expedia #booking #priceline #kayak... See more

PREVIOUS STORIES

To read the web version of previous stories, click here

If you have any comments or feedback, just respond to this email.

Thanks for reading,
Kieran & Justin Ryan